替诺福韦抗病毒治疗的相关肾损害
|
摘要
<正>替诺福韦(tenofovir,TDF)作为一种新型核苷酸类反转录酶抑制剂,于2001年10月,美国食品药品监督管理局(FDA)已批准其用于人类免疫缺陷病毒(HIV)感染的治疗,2008年8月又获准用于治疗慢性乙型肝炎(CHB)。2013年TDF进入中国并用于治疗HIV感染,2014年获准用于
引文
[1]YUEN M F,LAI C L.Treatment of chronic hepatitis B:evolution over two decades[J].J Gastroenterol Hepatol,2011,26(Suppl 1):138-143.
[2]MONTEIRO N,BRANCO M,PERES S,et al.The impact of tenofovir disoproxil fumarate on kidney function:four-year data from the HIV-infected outpatient cohort[J].J Int AIDS Soc,2014,17(4 Suppl 3):19565.
[3]VERHELST D,MONGE M,MEYNARD J L,et al.Fanconi syndrome and renal failure induced by tenofovir:a first case report[J].Am J Kidney Dis,2002,40(6):1331-1333.
[4]MEDLAND N A,CHOW E P,WALKER R G,et al.Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate[J].Int J STD AIDS,2018,29(3):227-236.
[5]LABARGA P,BAREIRO P,MARTIN-CARBONERO L,et al.Kidney tubular abnormali-ties in the absence of impaired glomerular function in HIV patients treated with tenofovir[J].AIDS,2009,23(6):689-696.
[6]曹颖,韩扬,谢静,等.含替诺福韦与克力芝的HAART方案对HIV/AIDS病人肾功能的影响[J].中国艾滋病性病,2013,19(10):715-718,729.
[7]HORBERG M,TANG B,TOWNER W,et al.Impact of tenofovir on renal function in HIV-infected,antiretroviral-naive patients[J].J Acquir Immune Defic Syndr,2010,53(1):62-69.
[8]吴亚松,张福杰.替诺福韦肾脏毒性及其遗传易感性[J].中国病原生物学杂志,2010,5(7):539-540,543.
[9]NISHIJIMA T,GATANAGA H,KOMATSU H,et al.Renal function declines more in tenofovir-than abacavir-based antiretroviral therapy in low-body weight treat-ment-naive patients with HIV infection[J].PLoS One,2012,7(1):e29977.
[10]张悦,吕洋,李旭,等.替诺福韦治疗慢性乙型肝炎的最新进展[J].临床肝胆病杂志,2015,31(4):599-602.
[11]喻婉莹,黄洁,阳国平.替诺福韦的肾毒性及其遗传药理学研究状况[J].中国临床药理学杂志,2015,31(14):1459-1461.
[12]王爽,闻颖.替诺福韦酯在不同人群中致肾脏损伤风险因素的研究进展[J].医学综述,2016,22(8):1543-1547.
[13]GRACEY D M,SNELLING P,MCKENZIE P,et al.Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection[J].Antivir Ther,2013,18(7):945-948.
[14]HWANG H S,PARK C W,SONG M J.Tenofovir-associated fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection[J].Hepatology,2015,62(4):1318-1320.
[15]于洁,黄玉仙.替诺福韦酯治疗慢性乙型肝炎的进展[J].中国感染与化疗杂志,2012,12(1):76-80.
[16]郭红英,张继明.替诺福韦酯治疗慢性乙型肝炎的研究进展[J].世界临床药物,2007,28(12):734-737.
[17]PRADAT P,LE POGAM M A,OKON J B,et al.Evolution of glomerular filtration rate in HIV-infected,HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate[J].J Viral Hepat,2013,20(9):650-657.
[18]刘慧,李小青,战寒秋.治疗慢性乙型肝炎新药替诺福韦酯研究进展[J].中国药学杂志,2012,47(18):1441-1443.
[19]DE VRIES-SLUIJS T E,REIJNDERS J G,HANSEN B E,et al.Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis Bvirus[J].Gastroenterology,2010,139(6):1934-1941.
[20]ZIMMERMANN A E,PIZZOFERRATO T,BEDFORD J,et al.Tenofovir-associated acute and chronic kidney disease:a case of multiple drug interac-tions[J].Clin Infect Dis,2006,42(2):283-290.
[21]刘旭辉,赵小丽,杨萱,等.河南省首例艾滋病病人替诺福韦治疗导致范可尼综合征[J].中国艾滋病性病,2011,17(5):593,599.
[22]KARRAS A,LAFAURIE M,FURCO A,et al.Tenofovirrelated nephrotoxicity in human immunodeficiency virus-infected patients:three cases of renal failure,Fanconi syndrome,and nephrogenic diabetes insipidus[J].Clin Infect Dis,2003,36(8):1070-1073.
[23]JAFARI A,KHALILI H,DASHTI-KHAVIDAKI S,et al.Tenofovir-induced nephrotoxicity:incidence,mechanism,risk factors,prognosis and proposed agents for prevention[J].Eur J Clin Pharmacol,2014,70(9):1029-1040.
[24]LEWIS W,DAY B J,COPELAND W C.Mitochondrial toxicity of NRTI antiviral drugs:an integrated cellular perspective[J].Nat Rev Drug Discov,2003,2(10):812-822.
[25]ABRAHAM P,RAMAMOORTHY H,ISAAC B.Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate-induced mitochondrial dam-age and increased oxidonitrosative stress in the kidney[J].J Biomed Sci,2013,20(1):61.
[26]KOHLER J J,HOSSEINI S H,GREEN E,et al.Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4transporters[J].Lab Invest,2011,91(6):852-858.
[27]RYOM L,MOCROFT A,KIRK O,et al.Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function:the D:A:D study[J].J Infect Dis,2013,207(9):1359-1369.
[28]REICHEL V,MASEREEUW R,VAN DEN HEUVEL J J,et al.Transport of a fluores-cent cAMP analog in teleost proximal tubules[J].Am J Physiol Regul Integr Comp Physiol,2007,293(6):R2382-2389.
[29]WEISS J,THEILE D,KETABI-KIYANVASH N,et al.Inhibition of MRP1/ABCC1,MRP2/ABCC2,and MRP3/ABCC3 by nucleoside,nucleotide,and non-nucleoside re-verse transcriptase inhibitors[J].Drug Meta Dispos,2007,35(3):340-344.
[30]FERNANDEZ-FERNANDEZ B,MONTOYA-FERRER A,SANZ A B,et al.Tenofovir nephro-toxicity:2011 update[J].AIDS Res Treat,2011,2011:354908.
[31]HERLITZ L C,MOHAN S,STOKES M B,et al.Tenofovir nephrotoxicity:acute tubular necrosis with distinctive clinical,pathological,and mitochondrial abnormalities[J].Kidney Int,2010,78(11):1171-1177.
[32]HALL A M,HENDRY B M,NITSCH D,et al.Tenofovirassociated kidney toxicity in HIV-infected patients:a review of the evidence[J].Am J Kidney Dis,2011,57(5):773-780.
[33]NELSON M R,KATLAMA C,MONTANER J S,et al.The safety of tenofovir diso-proxil fumarate for the treatment of HIVinfection in adults:the first 4 years[J].AIDS,2007,21(10):1273-1281.
[34]薛晓拉,陈媛媛,王延涛,等.替诺福韦酯相关肾毒性研究进展[J].当代医学,2017,23(13):179-182.
[35]DEL PALACIO M,ROMERO S,CASADO J L.Proximal tubular renal dysfunction or damage in HIV-infected patients[J].AIDS Rev,2012,14(3):179-187.
[36]陈方方,王岚,韩娟,等.河南省驻马店市HIV单阳家庭阴性配偶抗体阳转率及其影响因素研究[J].中华流行病学杂志,2013,34(1):10-14.
[37]官丽倩,张仁芳.替诺福韦酯相关性肾毒性的研究进展[J].世界临床药物,2014,35(7):444-447.
[2]MONTEIRO N,BRANCO M,PERES S,et al.The impact of tenofovir disoproxil fumarate on kidney function:four-year data from the HIV-infected outpatient cohort[J].J Int AIDS Soc,2014,17(4 Suppl 3):19565.
[3]VERHELST D,MONGE M,MEYNARD J L,et al.Fanconi syndrome and renal failure induced by tenofovir:a first case report[J].Am J Kidney Dis,2002,40(6):1331-1333.
[4]MEDLAND N A,CHOW E P,WALKER R G,et al.Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate[J].Int J STD AIDS,2018,29(3):227-236.
[5]LABARGA P,BAREIRO P,MARTIN-CARBONERO L,et al.Kidney tubular abnormali-ties in the absence of impaired glomerular function in HIV patients treated with tenofovir[J].AIDS,2009,23(6):689-696.
[6]曹颖,韩扬,谢静,等.含替诺福韦与克力芝的HAART方案对HIV/AIDS病人肾功能的影响[J].中国艾滋病性病,2013,19(10):715-718,729.
[7]HORBERG M,TANG B,TOWNER W,et al.Impact of tenofovir on renal function in HIV-infected,antiretroviral-naive patients[J].J Acquir Immune Defic Syndr,2010,53(1):62-69.
[8]吴亚松,张福杰.替诺福韦肾脏毒性及其遗传易感性[J].中国病原生物学杂志,2010,5(7):539-540,543.
[9]NISHIJIMA T,GATANAGA H,KOMATSU H,et al.Renal function declines more in tenofovir-than abacavir-based antiretroviral therapy in low-body weight treat-ment-naive patients with HIV infection[J].PLoS One,2012,7(1):e29977.
[10]张悦,吕洋,李旭,等.替诺福韦治疗慢性乙型肝炎的最新进展[J].临床肝胆病杂志,2015,31(4):599-602.
[11]喻婉莹,黄洁,阳国平.替诺福韦的肾毒性及其遗传药理学研究状况[J].中国临床药理学杂志,2015,31(14):1459-1461.
[12]王爽,闻颖.替诺福韦酯在不同人群中致肾脏损伤风险因素的研究进展[J].医学综述,2016,22(8):1543-1547.
[13]GRACEY D M,SNELLING P,MCKENZIE P,et al.Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection[J].Antivir Ther,2013,18(7):945-948.
[14]HWANG H S,PARK C W,SONG M J.Tenofovir-associated fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection[J].Hepatology,2015,62(4):1318-1320.
[15]于洁,黄玉仙.替诺福韦酯治疗慢性乙型肝炎的进展[J].中国感染与化疗杂志,2012,12(1):76-80.
[16]郭红英,张继明.替诺福韦酯治疗慢性乙型肝炎的研究进展[J].世界临床药物,2007,28(12):734-737.
[17]PRADAT P,LE POGAM M A,OKON J B,et al.Evolution of glomerular filtration rate in HIV-infected,HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate[J].J Viral Hepat,2013,20(9):650-657.
[18]刘慧,李小青,战寒秋.治疗慢性乙型肝炎新药替诺福韦酯研究进展[J].中国药学杂志,2012,47(18):1441-1443.
[19]DE VRIES-SLUIJS T E,REIJNDERS J G,HANSEN B E,et al.Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis Bvirus[J].Gastroenterology,2010,139(6):1934-1941.
[20]ZIMMERMANN A E,PIZZOFERRATO T,BEDFORD J,et al.Tenofovir-associated acute and chronic kidney disease:a case of multiple drug interac-tions[J].Clin Infect Dis,2006,42(2):283-290.
[21]刘旭辉,赵小丽,杨萱,等.河南省首例艾滋病病人替诺福韦治疗导致范可尼综合征[J].中国艾滋病性病,2011,17(5):593,599.
[22]KARRAS A,LAFAURIE M,FURCO A,et al.Tenofovirrelated nephrotoxicity in human immunodeficiency virus-infected patients:three cases of renal failure,Fanconi syndrome,and nephrogenic diabetes insipidus[J].Clin Infect Dis,2003,36(8):1070-1073.
[23]JAFARI A,KHALILI H,DASHTI-KHAVIDAKI S,et al.Tenofovir-induced nephrotoxicity:incidence,mechanism,risk factors,prognosis and proposed agents for prevention[J].Eur J Clin Pharmacol,2014,70(9):1029-1040.
[24]LEWIS W,DAY B J,COPELAND W C.Mitochondrial toxicity of NRTI antiviral drugs:an integrated cellular perspective[J].Nat Rev Drug Discov,2003,2(10):812-822.
[25]ABRAHAM P,RAMAMOORTHY H,ISAAC B.Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate-induced mitochondrial dam-age and increased oxidonitrosative stress in the kidney[J].J Biomed Sci,2013,20(1):61.
[26]KOHLER J J,HOSSEINI S H,GREEN E,et al.Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4transporters[J].Lab Invest,2011,91(6):852-858.
[27]RYOM L,MOCROFT A,KIRK O,et al.Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function:the D:A:D study[J].J Infect Dis,2013,207(9):1359-1369.
[28]REICHEL V,MASEREEUW R,VAN DEN HEUVEL J J,et al.Transport of a fluores-cent cAMP analog in teleost proximal tubules[J].Am J Physiol Regul Integr Comp Physiol,2007,293(6):R2382-2389.
[29]WEISS J,THEILE D,KETABI-KIYANVASH N,et al.Inhibition of MRP1/ABCC1,MRP2/ABCC2,and MRP3/ABCC3 by nucleoside,nucleotide,and non-nucleoside re-verse transcriptase inhibitors[J].Drug Meta Dispos,2007,35(3):340-344.
[30]FERNANDEZ-FERNANDEZ B,MONTOYA-FERRER A,SANZ A B,et al.Tenofovir nephro-toxicity:2011 update[J].AIDS Res Treat,2011,2011:354908.
[31]HERLITZ L C,MOHAN S,STOKES M B,et al.Tenofovir nephrotoxicity:acute tubular necrosis with distinctive clinical,pathological,and mitochondrial abnormalities[J].Kidney Int,2010,78(11):1171-1177.
[32]HALL A M,HENDRY B M,NITSCH D,et al.Tenofovirassociated kidney toxicity in HIV-infected patients:a review of the evidence[J].Am J Kidney Dis,2011,57(5):773-780.
[33]NELSON M R,KATLAMA C,MONTANER J S,et al.The safety of tenofovir diso-proxil fumarate for the treatment of HIVinfection in adults:the first 4 years[J].AIDS,2007,21(10):1273-1281.
[34]薛晓拉,陈媛媛,王延涛,等.替诺福韦酯相关肾毒性研究进展[J].当代医学,2017,23(13):179-182.
[35]DEL PALACIO M,ROMERO S,CASADO J L.Proximal tubular renal dysfunction or damage in HIV-infected patients[J].AIDS Rev,2012,14(3):179-187.
[36]陈方方,王岚,韩娟,等.河南省驻马店市HIV单阳家庭阴性配偶抗体阳转率及其影响因素研究[J].中华流行病学杂志,2013,34(1):10-14.
[37]官丽倩,张仁芳.替诺福韦酯相关性肾毒性的研究进展[J].世界临床药物,2014,35(7):444-447.